BCL2 and B-cell chronic lymphocytic leukemia: The relevance of BCL-2 for disease pathophysiology and also susceptibility to treatment is clearly documented for other malignancies such as CLL or AML, where this mechanism is successfully targeted using therapeutics like the BCL-2 inhibitor Venetoclax [16,17].